Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients
Melanie Maechler(University of Bern), Thomas Pabst(University Hospital of Bern), Michael Daskalakis(University of Bern), Ulrike Bacher(Hattiesburg Clinic), Henning Nilius(University Hospital of Bern), Michael Nagler(University Hospital of Bern), Behrouz Mansouri Taleghani(University of Bern), Barbara Jeker(University of Bern)
Cited by 6
Related Papers
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
|Blood|2007|410
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
|Leukemia|2014|172
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
|Blood|2007|157
Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation
|British Journal of Haematology|2016|134